肝动脉化疗栓塞联合肿瘤间质治疗肝癌患者对外周血细胞免疫指标的影响

Changes of immune cells in the peripheral blood of patients with liver cancer after transcatheter arterial chemoembolization combined with interstitial therapy

目的：探讨肝癌患者应用肝动脉化疗栓塞联合肿瘤间质治疗对其外周血细胞免疫指标的影响。方法：选择2010年4月~2014年6月在我院接受治疗的48例肝癌患者,使用随机数字表法将其分成观察组和对照组,对照组患者应用肝动脉化疗栓塞予以治疗,观察组患者则应用肿瘤间质治疗联合肝动脉化疗栓塞予以治疗;另外选择24名正常体检者作为正常组,进行对照研究。对比两组患者的治疗效果、外周血细胞免疫指标的变化情况以及生存率情况。结果：经过相应的治疗后,观察组患者的治疗效果明显优于对照组患者（P〈0.05）;两组患者治疗前的CD3＋、CD4＋以及CD4＋/CD8＋水平无明显差异（P〉0.05）,并且都显著低于正常组（P〈0.05）;观察组患者治疗后的CD3＋、CD4＋以及CD4＋/CD8＋水平显著高于对照组患者（P〈0.05）;观察组患者治疗后1年以及2年的生存率都显著高于对照组患者（P〈0.05）。结论：肝癌患者应用肝动脉化疗栓塞联合肿瘤间质治疗,能够获得较好的临床疗效,同时能够有效促进患者自身免疫能力的提升、恢复,对于患者的预后具有重要的临床意义,值得临床推广。

Objective：To discuss the changes of immune cells in the peripheral blood of liver cancer patients after transcatheter arterial chemoembolization combined with interstitial therapy.Methods：A total of 48 cases ith liver cancer were selected,which were treated in our hospital from April 2010 to June 2014,and were divided into the observation group and control group using a random number table.The patients of control group were treated by transcatheter arterial chemoembolization.On the basis of the control group,the patients of observation group were treated with interstitial therapy.24 cases of normal subjects were also selected,which used as the normal group.Outcomes of treatment,survival situation and changes of peripheral blood cells of the immune parameters of two groups were observed and compared.Results：In the terms of efficacy,the patients of observation group were significantly better than those of control group（P〈0.05）;In the terms of the levels of CD3^＋,CD4^＋and CD4^＋/CD8^＋before the treatment,the patients of two groups did not show significant different（P〈0.05）,and they were all significantly lower than the normal group（P〈0.05）;In the terms of the levels of CD3^＋,CD4^＋and CD4^＋/CD8^＋after the treatment,the patients of observation group were significantly better than those of control group（P〈0.05）;In the terms of the 1-year survival rates and the 2-year survival rates,the patients of observation group were significantly better than those of control group（P〈0.05）.Conclusion：The patients with liver cancer can achieve better clinical efficacy after treated with hepatic arterial chemoembolization and tumor interstitial therapy.It can effectively promote the upgrading and the recovery of the patient＇s own immune system,and is of important clinical value.